Table 1.
Characteristics of male new users of statins, non-users, and glaucoma medication users
| Characteristic | Statin user† | Statin non-user | Glaucoma medication user |
|---|---|---|---|
| N | 80,282 | 184,538 | 7,331 |
| Age at index (yrs), Mean (SD) | 59.1 (10.6) | 58.7 (10.7) | 64.0 (10.2) |
| Year of index, n (%) | |||
| 1990-1999 | 13927 (17.4%) | 27525 (14.9%) | 3685 (50.3%) |
| 2000-2004 | 19171 (23.9%) | 39089 (21.2%) | 1221 (16.7%) |
| 2005-2009 | 25425 (31.7%) | 58649 (31.8%) | 1181 (16.1%) |
| 2010-2014 | 21759 (27.1%) | 59275 (32.1%) | 1244 (17.0%) |
| Follow-up time (yrs), Median (IQR) | 7.0 (7.5) | 5.9 (7.0) | 6.6 (8.3) |
| Age at exit (yrs), Mean (SD) | 66.6 (11.2) | 65.2 (11.2) | 71.7 (10.8) |
| Baseline drug use, n (%) | |||
| Non-statin lipid-lowering medications | 5802 (7.2%) | 3165 (1.7%) | 132 (1.8%) |
| Glaucoma medications | 2808 (3.5%) | 6495 (3.5%) | - |
| 5α-reductase inhibitors | 1599 (2.0%) | 4928 (2.7%) | 115 (1.6%) |
| α-blockers | 6781 (8.5%) | 17953 (9.7%) | 496 (6.8%) |
| Baseline comorbidities, n (%) | |||
| Benign prostatic hyperplasia | 8614 (10.7%) | 23030 (12.5%) | 951 (13.0%) |
| Diabetes | 20081 (25.0%) | 16438 (8.9%) | 949 (13.0%) |
| Hypertension | 39845 (30.3%) | 62665 (34.0%) | 2451 (33.4%) |
| Heart disease | 33082 (41.2%) | 37644 (20.4%) | 1854 (25.3%) |
| Hyperlipidemia‡ | 39825 (49.6%) | 26553 (14.4%) | 668 (9.1%) |
| Outcomes during follow-up, n (%) | |||
| Prostate cancer (PC) | 3157 (3.9%) | 5769 (3.1%) | 416 (5.7%) |
| Metastatic PC at diagnosis | 307 (0.4%) | 788 (0.4%) | 78 (1.1%) |
| Mortality among men with PC | |||
| Prostate cancer | 497 (0.6%) | 1138 (0.6%) | 135 (1.8%) |
| Other cancer | 164 (0.2%) | 378 (0.2%) | 57 (0.8%) |
| Non-cancer | 477 (0.6%) | 748 (0.4%) | 109 (1.5%) |
| Alive | 2019 (2.5%) | 3505 (1.9%) | 115 (1.6%) |
†
In comparing statin users with glaucoma medication users, users of both drugs were removed, reducing the statin user sample size to 77,453.
‡
ICD-9 272 is not specific to hyperlipidemia (includes other disorders of lipoid metabolism).